this post was submitted on 13 Apr 2025
652 points (96.8% liked)
Technology
69041 readers
5173 users here now
This is a most excellent place for technology news and articles.
Our Rules
- Follow the lemmy.world rules.
- Only tech related news or articles.
- Be excellent to each other!
- Mod approved content bots can post up to 10 articles per day.
- Threads asking for personal tech support may be deleted.
- Politics threads may be removed.
- No memes allowed as posts, OK to post as comments.
- Only approved bots from the list below, this includes using AI responses and summaries. To ask if your bot can be added please contact a mod.
- Check for duplicates before posting, duplicates may be removed
- Accounts 7 days and younger will have their posts automatically removed.
Approved Bots
founded 2 years ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
In the US the tax payer subsidizes almost all drug research. Between 2010 and 2019 the NIH spent $184 Billion on all but 2 drugs approved by the FDA.
It worked out to about $1.5 Billion for each R&D product with a novel target and about $600 mill for each R&D product with multiple targets.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10148199/
Or
https://jamanetwork.com/journals/jama-health-forum/fullarticle/2804378
The cost to develop each drug is between about $1 and $2.5 Billion
I'm not sure how much is subsidized outside of NIH but I'd imagine other countries are doing the same.
Why should companies own the whole IP or perhaps why should they have any ownership if most of the funding is from the public?
This is a great point. I know that some pharmas actually do internally funded research, it's a thing, it happens, but it's completely dwarfed by shareholder giveaways and government subsidies ofc.